Rapid uptake of biosimilars expected in US
Adoption of biosimilars is expected to be rapid in the US - at least in the field of nephrology.
Adoption of biosimilars is expected to be rapid in the US - at least in the field of nephrology.
A survey of nephrologists, conducted by BioTrends Research Group, found that more than 60 per cent plan to start prescribing the biosimilar epoetin alfa within 12 months of the drug's launch.
Comparable rates of uptake have already been recorded in Germany, where nephrologists have embraced the biosimilar.
Dr Andrew Merron, director of the Biosimilars Advisory Service, revealed that US nephrologists expect to prescribe the biosimilar darbepoetin alfa to a greater proportion of eligible patients than their counterparts in France and Germany.
"This suggests that biosimilar erythropoiesis-stimulating agents (ESAs) will experience deeper, as well as more rapid, market penetration in the United States than we've seen in Europe as a whole," he suggested.
However, adoption of biosimilar insulins by endocrinologists is not expected to be as rapid, with their market share forecast to reach just eight per cent by 2021, compared with 36 per cent for ESAs across the US, Europe and Japan.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...